Citadel Advisors’s Vor Biopharma VOR Stock Holding History

Citadel Advisors’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,725	Closed	-$166K	–	14334
2025 Q4	$166K	Buy	12,725 +8,205	+182%	+$153K	﹤0.01%	11202
2025 Q3	$220K	Buy	+4,520	New	+$182K	﹤0.01%	11059
2025 Q1	–	Sell	-105	Closed	-$2.33K	–	15651
2024 Q4	$2.33K	Buy	105 +100	+2,000%	+$1.66K	﹤0.01%	14096
2024 Q3	$70	Buy	+5	New	+$91	﹤0.01%	14095
2024 Q2	–	Sell	-5	Closed	-$237	–	15497
2024 Q1	$237	Buy	+5	New	+$220	﹤0.01%	14383
2023 Q4	–	Sell	-170	Closed	-$7.21K	–	15330
2023 Q3	$7.21K	Sell	170 -50	-23%	-$2.71K	﹤0.01%	13272
2023 Q2	$13.6K	Buy	220 +160	+267%	+$14.6K	﹤0.01%	13032
2023 Q1	$6.46K	Sell	60 -5	-8%	-$554	﹤0.01%	13805
2022 Q4	$8.64K	Buy	+65	New	+$6.43K	﹤0.01%	13737

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's VOR Position: Q1 2026 in Review

Citadel Advisors reduced its Vor Biopharma (VOR) stake by 66% in Q1 2026, selling an estimated $4.02M and leaving 148,768 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #5503.

Citadel Advisors first reported a position in VOR in Q4 2021 and has held it in 16 quarters since. The position peaked at $5.68M in Q4 2025. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

Citadel Advisors held 148,768 shares of Vor Biopharma worth $2.65M as of Q1 2026.
Citadel Advisors sold 285,126 Vor Biopharma shares in Q1 2026, an estimated $4.02M.
Vor Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5503 holding.
Citadel Advisors first reported a position in Vor Biopharma in Q4 2021 and has held it in 16 quarters since.
Citadel Advisors's Vor Biopharma position peaked at $5.68M in Q4 2025.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.